Franklin Templeton Investment Funds Sector Equity Franklin Biotechnology Discovery LU0195948822 31 August 2021 Fund Fund Fact Sheet For Professional Client Use Only. Not for distribution to Retail Clients. Fund Overview Performance Base Currency for Fund USD Performance over 5 Years in Share Class Currency (%) Total Net Assets (USD) 2,53 billion Franklin Biotechnology Discovery Fund I (acc) USD NASDAQ Biotechnology Index Fund Inception Date 03.04.2000 200 Number of Issuers 118 180 Benchmark NASDAQ Biotechnology Index 160 Morningstar Category™ Sector Equity Biotechnology 140 Summary of Investment Objective 120 The Fund aims to achieve capital appreciation by investing principally in equity securities of biotechnology companies 100 and discovery research firms mainly located in the US. Fund Management 80 08/16 02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 Evan McCulloch, CFA: United States Discrete Annual Performance in Share Class Currency (%) Wendy Lam, PhD: United States 08/20 08/19 08/18 08/17 08/16 Akiva Felt: United States 08/21 08/20 08/19 08/18 08/17 I (acc) USD 8,84 35,87 -14,04 4,91 22,51 Ratings - I (acc) USD Benchmark in USD 25,46 31,77 -15,82 10,07 18,81 Overall Morningstar Rating™: Performance in Share Class Currency (%) Asset Allocation Cumulative Annualised Since Since 1 Mth 3 Mths 6 Mths 1 Yr 3 Yrs 5 Yrs Incept 3 Yrs 5 Yrs Incept I (acc) USD 4,95 5,61 -5,76 8,84 27,12 63,37 566,42 8,33 10,32 11,80 Benchmark in USD 4,09 12,19 8,32 25,46 39,16 82,00 684,93 11,64 12,73 12,89 Category Average 3,58 5,59 1,19 15,43 28,74 66,22 459,16 8,79 10,70 10,66 % Calendar Year Performance in Share Class Currency (%) Equity 96,46 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Cash & Cash Equivalents 3,54 I (acc) USD 28,65 34,64 -15,60 17,95 -17,19 5,84 35,85 65,62 27,92 10,65 Benchmark in USD 25,69 24,41 -9,32 21,06 -21,68 11,42 34,32 65,97 32,29 12,08 Past performance is not an indicator or a guarantee of future performance. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Performance details provided are in share class currency, net income reinvested, gross of tax, net of management fees. Sales charges and other commissions, other taxes and relevant costs to be paid by an investor are not included in the calculations. Performance may also be affected by currency fluctuations. Up to date performance figures can be found on our local website. Top Ten Holdings (% of Total) Fund Measures Issuer Name P/E to Growth 1,84x REGENERON PHARMACEUTICALS INC 5,82 Historical 3 Yr Sales Growth 46,70% AMGEN INC 4,72 Estimated 3-5 Yr EPS Growth 0,29% ILLUMINA INC 4,53 Price to Earnings (12-mo 16,16x GILEAD SCIENCES INC 4,50 Forward) HORIZON THERAPEUTICS PLC 3,81 Standard Deviation (5 Yrs) 22,00% MODERNA INC 3,62 Sharpe Ratio (5 Yrs) 0,42 BIOGEN INC 3,47 Tracking Error (5 Yrs) 7,09% NOVAVAX INC 3,04 Information Ratio (5 Yrs) -0,34 MIRATI THERAPEUTICS INC 2,98 Beta (5 Yrs) 1,02 VERTEX PHARMACEUTICALS INC 2,96 Share Class Information (For a full list of available share classes, please visit your local website) Fees Dividends Fund Identifiers TER (%) Max. Annual Last Paid Last Paid Share Class Incept Date NAV 31.07.2021 Charge (%) Date Amount Bloomberg ID ISIN SEDOL I (acc) USD 31.08.2004 USD 66,64 0,96 0,70 N/A N/A TEMBDIA LX LU0195948822 B020F35 Tel Fax E-mail Web +46 (0) 8 545 01230 +46 (0) 8 545 01239 [email protected] www.franklintempletonnordic.com Franklin Biotechnology Discovery Fund 31 August 2021 For Professional Client Use Only. Not for distribution to Retail Clients. Composition of Fund Market Capitalisation Breakdown in USD % of Equity Performance Attribution by Country <2,0 Billion 21,35 01.09.2020-31.08.2021 Total Effect 2,0-5,0 Billion 15,53 United Kingdom 1,69 5,0-10,0 Billion 15,58 France 0,15 10,0-25,0 Billion 11,13 Israel 0,05 25,0-50,0 Billion 2,52 Belgium -0,02 >50,0 Billion 33,26 Spain -0,03 N/A 0,63 Sweden -0,04 Netherlands -0,08 Performance Attribution by Security Ireland -0,10 01.09.2020-31.08.2021 Total Effect Switzerland -0,16 5 Largest Contributing Securities Canada -0,26 IMMUNOMEDICS INC 2,41 China -0,28 GW PHARMACEUTICALS PLC 2,03 Denmark -0,40 NOVAVAX INC 0,87 Germany -1,67 FATE THERAPEUTICS INC 0,83 United States -13,00 *INCYTE CORP 0,81 Cash & Cash Equivalents -1,44 5 Smallest Contributing Securities GLOBAL BLOOD THERAPEUTICS INC -0,86 DECIPHERA PHARMACEUTICALS INC -0,98 IOVANCE BIOTHERAPEUTICS INC -1,08 BIONTECH SE -1,43 MODERNA INC -8,69 *Security not held in the portfolio at the end of the reporting period. Largest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Regeneron Pharmaceuticals, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,98 Novavax, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,95 Trillium Therapeutics Inc. Pharmaceuticals Biotechnology & Life Sciences Canada 0,73 Ascendis Pharma A/S Sponsored ADR Pharmaceuticals Biotechnology & Life Sciences Denmark 0,66 PTC Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,32 Gilead Sciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,32 Horizon Therapeutics Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States 0,31 Seagen, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,24 Sutro Biopharma, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,24 Adagio Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States 0,23 Smallest Contributing Securities 01.08.2021-31.08.2021 Contribution to Return % Jazz Pharmaceuticals Public Limited Company Pharmaceuticals Biotechnology & Life Sciences United States -0,62 Illumina, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,43 Amgen Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,34 Reata Pharmaceuticals, Inc. Class A Pharmaceuticals Biotechnology & Life Sciences United States -0,29 Fate Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,21 Zogenix, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,11 Heron Therapeutics Inc Pharmaceuticals Biotechnology & Life Sciences United States -0,10 Arcus Biosciences, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,09 ACADIA Pharmaceuticals Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,09 Silverback Therapeutics, Inc. Pharmaceuticals Biotechnology & Life Sciences United States -0,07 What Are the Key Risks? The value of shares in the Fund and income received from it can go down as well as up and investors may not get back the full amount invested. Performance may also be affected by currency fluctuations. Currency fluctuations may affect the value of overseas investments. The Fund invests mainly in equity securities of biotechnology companies. Such securities have historically been subject to significant price movements that may occur suddenly due to market, sector or company-specific factors. As a result, the performance of the Fund can fluctuate very significantly over relatively short time periods. Other significant risks include: securities lending risk, equity risk. For full details of all of the risks applicable to this Fund, please refer to the “Risk Considerations” section of the Fund in the current prospectus of Franklin Templeton Investment Funds. Important Information This document is intended to be of general interest only and does not constitute legal or tax advice nor is it an offer for shares or invitation to apply for shares of the Franklin Templeton Investment Funds (the Fund). Nothing in this document should be construed as investment advice. Opinions expressed are the author’s at publication date and they are subject to change without prior notice. The value of shares in the Fund and income received from it can go down as well as up, and investors may not get back the full amount invested. Past performance is not an indicator or a guarantee of future performance. Currency fluctuations may affect the value of overseas investments. When investing in a fund denominated in a foreign currency, your performance may also be affected by currency fluctuations. An investment in the Fund entails risks which are described in the Fund's prospectus and the relevant Key Investor Information Document. In emerging markets, the risks can be greater than in developed markets. Investments in derivative instruments entail specific risks that may increase the risk profile of the fund and are more fully described in the Fund’s prospectus and in the relevant Key Investor Information Document. No shares of the Fund may be directly or indirectly offered or sold to residents of the United States of America. Any research and analysis contained in this document has been procured by Franklin Templeton for its own purposes and is provided to you only incidentally. References to particular industries, sectors or companies are for general information and are not necessarily indicative of a fund’s holding at any one time. Please consult your financial advisor before deciding to invest. Subscriptions to shares of the Fund can only be made on the basis of the current prospectus, the relevant Key Investor Information Document, accompanied by the latest available audited annual report and the latest semi-annual report if published thereafter.